Mirador Therapeutics licenses Kira Pharmaceuticals' KP-301 for $12M to treat ANCA-associated vasculitis, competing with Amgen's Tavneos.
Mirador Therapeutics, the secretive immune disease biotech with more than $650 million in VC funding, is finally revealing a piece of its pipeline.
The San …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Mirador Therapeutics Expands Precision Immunology Portfolio with Exclusive License to KP-301, a Long-Acting Anti-C5a…
With all eyes on Tavneos’ seemingly precarious approval status in the U.S., Amgen is advancing plans to defend the…
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired…
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand…
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival…
Vedana Therapeutics exits stealth with $46M Series A to develop anti-PACAP and bispecific PACAP/CGRP treatments for migraine…
